Table 3.
Adjusted hazard ratio for hospitalizations due to heart failure based on decline in estimated glomerular filtration rate at 2- and 6-week time point following randomization, using 3 different levels of hemodynamic effect of enalapril.
| eGFR Decline | 0% OF DECLINE IN ENALAPRIL GROUP DUE TO HEMODYNAMIC EFFECT Magnified Estimate |
100% OF DECLINE IN ENALAPRIL GROUP TO HEMODYNAMIC EFFECT Conservative Estimate |
50% OF DECLINE IN ENALPRIL GROUP DUE TO HEMODYNAMIC EFFECT Intermediate Estimate |
|||
|---|---|---|---|---|---|---|
| Reference (% Decline with Placebo) |
HR (95% CI) | Reference (% Decline with Placebo) |
HR (95% CI) | Reference (% Decline with Placebo) |
HR (95% CI) | |
| at 2-Weeks | ||||||
| 5% | 5% | 0.57 (0.51, 0.65) | 0% | 0.60 (0.53, 0.68) | 2.5% | 0.59 (0.52, 0.66) |
| 10% | 10% | 0.57 (0.50, 0.65) | 0% | 0.62 (0.54, 0.72) | 5% | 0.60 (0.53, 0.68) |
| 15% | 15% | 0.57 (0.49, 0.65) | 0% | 0.65 (0.55, 0.76) | 7.5% | 0.61 (0.53, 0.70) |
| 20% | 20% | 0.56 (0.48, 0.66) | 0% | 0.68 (0.58, 0.80) | 10% | 0.62 (0.54, 0.72) |
| 25% | 25% | 0.56 (0.47, 0.67) | 0% | 0.71 (0.59, 0.85) | 12.5% | 0.63 (0.53, 0.75) |
| 30% | 30% | 0.56 (0.46, 0.68) | 0% | 0.74 (0.61, 0.91) | 15% | 0.65 (0.53, 0.79) |
| 35% | 35% | 0.55 (0.44, 0.69) | 0% | 0.78 (0.61, 0.98) | 17.5% | 0.66 (0.52, 0.84) |
| 40% | 40% | 0.55 (0.43, 0.70) | 0% | 0.81 (0.62, 1.07) | 20% | 0.67 (0.51, 0.88) |
| at 6-Weeks | ||||||
| 5% | 5% | 0.58 (0.51, 0.65) | 0% | 0.62 (0.55, 0.71) | 2.5% | 0.60 (0.53, 0.68) |
| 10% | 10% | 0.57 (0.51, 0.65) | 0% | 0.67 (0.58, 0.77) | 5% | 0.62 (0.54, 0.70) |
| 15% | 15% | 0.57 (0.49, 0.65) | 0% | 0.71 (0.60, 0.83) | 7.5% | 0.63 (0.55, 0.72) |
| 20% | 20% | 0.56 (0.48, 0.66) | 0% | 0.74 (0.63, 0.87) | 10% | 0.63 (0.55, 0.73) |
| 25% | 25% | 0.56 (0.47, 0.67) | 0% | 0.77 (0.64, 0.91) | 12.5% | 0.64 (0.54, 0.75) |
| 30% | 30% | 0.56 (0.46, 0.68) | 0% | 0.79 (0.65, 0.96) | 15% | 0.64 (0.53, 0.78) |
| 35% | 35% | 0.55 (0.44, 0.69) | 0% | 0.82 (0.66, 1.02) | 17.5 | 0.65 (0.51, 0.81) |
| 40% | 40% | 0.55 (0.43, 0.70) | 0% | 0.85 (0.66, 1.10) | 20% | 0.65 (0.50, 0.84) |
Cox proportional hazard regression models used to evaluate association between enalapril and heart failure hospitalizations at varying levels of %eGFR decline at 2- and 6-weeks after randomization. Analysis performed using 3 different levels of hemodynamic decline from enalapril itself: (1) assuming none (0%) of eGFR decline in the enalapril group was due to hemodynamic effect and thus the reference group comprised placebo patients with equal %eGFR decline; (2) assuming all (100%) of the eGFR decline in the enalapril group was due to hemodynamic effect and thus the reference group comprised placebo patients with 0% eGFR decline; (3) assuming that half (50%) of the eGFR decline in the enalapril group was due to hemodynamic effect and thus the reference group comprised placebo patients with half %eGFR decline. Models adjusted for age, sex, race, previous myocardial infarction, smoking, NYHA functional class, diastolic blood pressure, baseline eGFR, potassium, hematocrit, and trial (Prevention or Treatment).